Evaluation of inactivated and live attenuated, tetravalent dengue vaccine prime-boost strategies in a randomized, open-label, phase I study: implications for understanding immune correlates of protection.
Michael Koren, Simon Pollett, Keisha Akerele et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized, open-label, phase I study evaluated the immune responses elicited by a tetravalent purified inactivated vaccine (PIV) prime and a live attenuated vaccine (LAV) boost in 40 healthy adults. Both 0, 90-day and 0, 180-day PIV/LAV schedules produced similar immune responses to all four dengue virus types, but the shorter schedule resulted in more severe adverse events. Subsequent challenges revealed unprotected vaccinees experienced increased dengue-like illness compared to controls.
Key findings
- Both PIV/LAV regimens elicited high and balanced immune responses to DENV 1-4.
- The 0, 90-day schedule was associated with more severe adverse events.
- Vaccinees challenged with DENV-1 were mostly unprotected and had increased symptom severity.
Why it matters
Understanding the immune correlates of protection against dengue is crucial for developing effective vaccines. This study highlights the complexities of vaccine-induced immunity and the potential for increased disease severity, which can inform future vaccine development strategies.